Among the most promising pharmacological agents targeting downstream signaling mediators shared by both IGF-IR and RTKs, the combination of anti-mTOR compounds with different kinase inhibitors has generated encouraging reductions in tumor growth [48]. Here, IGF1R is linked to neoplasm.